REGENERON PHARMACEUTICALS, INC. (REGN) Current Ratio
- Current ratio · latest quarter: Value 3.34×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.34× | Current assets / current liabilities. $18.45B ÷ $5.53B ≈ 3.34× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 18.45B USD | Assets, Current |
| Current obligations | 5.53B USD | Liabilities, Current |
| Cash and equivalents | 2.46B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 5.54B USD | Marketable Securities, Current |
| Customer receivables | 6.57B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 3.08B USD | Inventory, Net |
| Payables | 1.16B USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.45B | $5.53B | $2.46B | $5.54B | $6.57B | $3.08B | $1.16B | (m) | 3.34× |
| 2026-03-31 | $18.21B | $5.11B | $2.96B | $5.79B | $5.73B | $3.10B | $1.03B | (m) | 3.57× |
| 2025-12-31 | $18.02B | $4.37B | $3.12B | $5.49B | $5.74B | $3.20B | $939.00M | (m) | 4.13× |
| 2025-09-30 | $17.98B | $4.43B | $2.51B | $5.94B | $5.69B | $3.25B | $903.80M | (m) | 4.06× |
| 2025-06-30 | $16.86B | $3.67B | $2.00B | $5.47B | $5.61B | $3.21B | $723.90M | (m) | 4.60× |
| 2025-03-31 | $17.57B | $3.57B | $3.09B | $5.26B | $5.56B | $3.19B | $705.50M | (m) | 4.93× |
| 2024-12-31 | $18.66B | $3.94B | $2.49B | $6.52B | $6.21B | $3.09B | $789.50M | (m) | 4.73× |
| 2024-09-30 | $19.33B | $3.66B | $2.01B | $7.78B | $6.11B | $3.02B | $497.30M | (m) | 5.28× |
| 2024-06-30 | $19.08B | $3.51B | $1.92B | $7.89B | $5.72B | $2.87B | $561.70M | (m) | 5.44× |
| 2024-03-31 | $18.87B | $3.58B | $2.60B | $7.92B | $5.22B | $2.71B | $671.30M | (m) | 5.27× |
| 2023-12-31 | $19.48B | $3.42B | $2.73B | $8.11B | $5.67B | $2.58B | $606.60M | (m) | 5.69× |
| 2023-09-30 | $18.63B | $3.60B | $2.15B | $7.76B | $5.58B | $2.56B | $536.60M | (m) | 5.18× |
| 2023-06-30 | $16.92B | $3.10B | $1.94B | $6.99B | $5.12B | $2.51B | $547.30M | (m) | 5.45× |
| 2023-03-31 | $16.91B | $3.10B | $3.92B | $5.04B | $5.12B | $2.42B | $599.50M | (m) | 5.45× |
| 2022-12-31 | $15.88B | $3.14B | $3.11B | $4.64B | $5.33B | $2.40B | $589.20M | (m) | 5.06× |
| 2022-09-30 | $15.43B | $2.88B | $3.49B | $3.53B | $5.55B | $2.41B | (m) | (m) | 5.36× |
| 2022-06-30 | $15.53B | $3.03B | $3.40B | $4.17B | $5.16B | $2.22B | (m) | (m) | 5.12× |
| 2022-03-31 | $14.31B | $3.01B | $3.35B | $3.70B | $4.84B | $1.99B | (m) | (m) | 4.76× |
| 2021-12-31 | $14.01B | $3.93B | $2.89B | $2.81B | $6.04B | $1.95B | $564.00M | (m) | 3.56× |
| 2021-09-30 | $13.78B | $3.71B | $3.43B | $2.36B | $5.45B | $2.05B | (m) | (m) | 3.71× |
| 2021-06-30 | $13.34B | $3.73B | $2.07B | $1.84B | $7.00B | $1.98B | (m) | (m) | 3.57× |
| 2021-03-31 | $10.06B | $3.22B | $1.44B | $2.07B | $4.17B | $2.16B | (m) | (m) | 3.12× |
| 2020-12-31 | $9.78B | $2.70B | $2.19B | $1.39B | $4.11B | $1.92B | $475.50M | (m) | 3.63× |
| 2020-09-30 | $9.10B | $2.34B | $1.57B | $1.45B | $3.09B | $1.80B | (m) | (m) | 3.89× |
| 2020-06-30 | $7.86B | $3.70B | $1.99B | $1.15B | $1.99B | $1.64B | (m) | (m) | 2.12× |
| 2020-03-31 | $8.64B | $2.06B | $2.21B | $1.80B | $2.06B | $1.48B | (m) | (m) | 4.21× |
| 2019-12-31 | $7.69B | $2.10B | $1.62B | $1.60B | $2.10B | $1.42B | $418.10M | (m) | 3.67× |
| 2019-09-30 | $7.11B | $1.77B | $1.38B | $1.49B | $2.03B | $1.34B | (m) | (m) | 4.03× |
| 2019-06-30 | $6.65B | $1.71B | $1.05B | $1.62B | $1.92B | $1.32B | (m) | (m) | 3.88× |
| 2019-03-31 | $6.93B | $1.51B | $1.71B | $1.52B | $1.73B | $1.21B | (m) | (m) | 4.58× |
| 2018-12-31 | $6.45B | $1.44B | $1.47B | $1.34B | $1.72B | $1.15B | $218.20M | (m) | 4.47× |
| 2018-09-30 | $5.72B | $1.42B | $1.09B | $1.10B | $1.67B | $1.04B | (m) | (m) | 4.04× |
| 2018-06-30 | $4.81B | $1.33B | $917.88M | $765.64M | $1.53B | $928.55M | (m) | (m) | 3.62× |
| 2018-03-31 | $4.54B | $1.27B | $1.02B | $605.46M | $1.53B | $820.40M | (m) | (m) | 3.59× |
| 2017-12-31 | $4.33B | $1.14B | $812.70M | $596.80M | $1.54B | $726.10M | $178.20M | (m) | 3.82× |
| 2017-09-30 | $4.14B | $1.14B | $792.07M | $586.88M | $1.53B | $641.59M | (m) | (m) | 3.63× |
| 2017-06-30 | $3.86B | $1.03B | $744.31M | $523.54M | $1.42B | $554.32M | (m) | (m) | 3.75× |
| 2017-03-31 | $3.67B | $1.31B | $811.77M | $495.31M | $1.34B | $466.58M | (m) | (m) | 2.80× |
| 2016-12-31 | $3.18B | $1.24B | $535.20M | $503.48M | $1.34B | $399.36M | (m) | (m) | 2.56× |
| 2016-09-30 | $3.50B | $961.18M | $920.36M | $488.03M | $1.33B | $345.62M | (m) | (m) | 3.64× |
| 2016-06-30 | $3.21B | $951.56M | $646.51M | $398.66M | $1.43B | $316.07M | (m) | (m) | 3.37× |
| 2016-03-31 | $3.13B | $919.72M | $604.21M | $244.97M | $1.45B | $303.29M | (m) | (m) | 3.41× |
| 2015-12-31 | $2.92B | $811.16M | $809.10M | $236.12M | $1.15B | $238.58M | (m) | (m) | 3.59× |
| 2015-09-30 | $2.68B | $734.99M | $654.59M | $241.06M | $1.09B | $190.67M | (m) | (m) | 3.64× |
| 2015-06-30 | $2.28B | $601.54M | $390.55M | $213.69M | $1.07B | $171.27M | (m) | (m) | 3.80× |
| 2015-03-31 | $2.31B | $536.13M | $507.91M | $234.26M | $1.02B | $133.86M | (m) | (m) | 4.31× |
| 2014-12-31 | $2.08B | $654.66M | $648.72M | $251.76M | $739.38M | $128.86M | (m) | (m) | 3.18× |
| 2014-09-30 | $2.20B | $410.20M | $646.55M | $395.65M | $673.91M | $120.32M | (m) | (m) | 5.36× |
| 2014-06-30 | $1.92B | $351.58M | $600.13M | $216.77M | $664.08M | $109.90M | (m) | (m) | 5.46× |
| 2014-03-31 | $1.87B | $305.07M | $461.86M | $186.28M | $801.77M | $86.55M | (m) | (m) | 6.13× |
| 2013-12-31 | $1.80B | $298.83M | $535.61M | $158.38M | $787.07M | $70.35M | (m) | (m) | 6.01× |
| 2013-09-30 | $1.63B | $268.73M | $263.21M | $182.11M | $855.84M | $63.29M | (m) | (m) | 6.08× |
| 2013-06-30 | $1.56B | $203.80M | $381.68M | $155.83M | $767.87M | $57.16M | (m) | (m) | 7.66× |
| 2013-03-31 | $1.31B | $197.24M | $180.36M | $127.35M | $703.86M | $43.98M | (m) | (m) | 6.63× |
| 2012-12-31 | $1.21B | $163.55M | $230.28M | $77.82M | $593.21M | $28.64M | (m) | (m) | 7.37× |
| 2012-09-30 | $948.60M | $178.57M | $119.00M | $143.55M | $506.68M | $29.57M | (m) | (m) | 5.31× |
| 2012-06-30 | $769.19M | $183.22M | $171.94M | $129.08M | $349.64M | $10.50M | (m) | (m) | 4.20× |
| 2012-03-31 | $696.91M | $160.39M | $394.58M | $37.71M | $159.46M | $6.20M | (m) | (m) | 4.35× |
| 2011-12-31 | $665.78M | $148.27M | $483.61M | $43.33M | $28.25M | $16.61M | (m) | (m) | 4.49× |
| 2011-09-30 | $339.87M | $133.24M | $206.40M | $39.10M | $3.66M | (m) | (m) | (m) | 2.55× |
| 2011-06-30 | $413.27M | $135.87M | $254.31M | $55.37M | $2.92M | (m) | (m) | (m) | 3.04× |
| 2011-03-31 | $325.50M | $112.25M | $135.38M | $91.06M | $3.77M | (m) | (m) | (m) | 2.90× |
| 2010-12-31 | $357.62M | $109.06M | $112.57M | $136.80M | $2.31M | (m) | (m) | (m) | 3.28× |
| 2010-09-30 | $575.72M | $133.83M | $325.29M | $153.77M | $3.05M | (m) | (m) | (m) | 4.30× |
| 2010-06-30 | $417.75M | $119.57M | $112.00M | $194.34M | $4.07M | (m) | (m) | (m) | 3.49× |
| 2009-12-31 | $425.51M | $93.58M | $207.07M | $134.25M | $2.87M | (m) | (m) | (m) | 4.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |